As of June 10, 2025, Innovation Pharmaceuticals Inc (IPIX) reports a ROE (Return on Equity) of -155.37%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Innovation Pharmaceuticals Inc's ROE (Return on Equity)
Over recent years, Innovation Pharmaceuticals Inc's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2023-06-30 | -155.37% |
| 2022-06-30 | -148.86% |
| 2021-06-30 | -184.74% |
| 2020-06-30 | -454.72% |
| 2019-06-30 | 210.24% |
This slight downward trend highlights how Innovation Pharmaceuticals Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Innovation Pharmaceuticals Inc's ROE (Return on Equity) to Peers
To better understand Innovation Pharmaceuticals Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Innovation Pharmaceuticals Inc (IPIX) | -155.37% |
| Oragenics Inc (OGEN) | 4987.46% |
| GT Biopharma Inc (GTBP) | 788.14% |
| Cyclacel Pharmaceuticals Inc (CYCC) | 515.73% |
| Xynomic Pharmaceuticals Holdings Inc (XYNO) | 111.26% |
| Sirona Biochem Corp (SBM.V) | 101.27% |
Compared to its competitors, Innovation Pharmaceuticals Inc's ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.